Finance entity
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Crinetics Pharmaceuticals, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Finance story that mention VK2735 Oral, all published on July 31, 2026.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Crinetics Pharmaceuticals, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Finance story that mention VK2735 Oral, all published on July 31, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering VK2735 Oral. Shared-story counts are live from our verified record — not editorial picks.
Vertex's $10B cash acquisition of Crinetics sets a powerful precedent, suggesting Viking Therapeutics could command a $15–20B price tag in a consolidating obesity market. For investors, VKTX's late-stage pipeline and the appetite of cash-rich pharma giants offer a high-risk, high-reward M&A setup.
VK2735 Oral is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
